Hepatocellular CarcinomaPhase 1NCT05003895
CAR-T cell
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
What the film says
Most liver cancer is the end of a long story. Decades of hepatitis, or alcohol, or fatty liver, scarring the organ until something breaks.
Fibrolamellar carcinoma is not that story. It turns up in teenagers and young adults with healthy livers and no risk factors at all. In this trial the median age was twenty-four, and the youngest patient twelve. It is rare: recent work estimates about six hundred new cases a year in the United States. Surgery can cure it, if the whole tumor can be removed. If it cannot, there is no standard drug treatment, and half of those patients live about a year.
But this cancer has an unusual feature. Its cause is known, and it is a single event.
In twenty fourteen, researchers sequenced these tumors and found that a stretch of chromosome nineteen, about four hundred thousand letters long, had gone missing. The deletion pulled two neighboring genes together and fused them into one. One makes a chaperone, a protein that helps other proteins fold. The other makes the working half of an enzyme called protein kinase A. Joined, they make a hybrid that still works as an enzyme, and that hybrid drives the cancer. It was in all fifteen tumors they examined, and in none of the normal liver beside them.
So block the hybrid enzyme. That was the obvious move, and it failed. Protein kinase A is essential everywhere in the body, and the drugs were too toxic to use. The field called the target undruggable.
Which leaves a different approach. Do not attack the protein. Point at it.
Where the two genes join, the protein has a seam, a short run of amino acids that exists in no healthy cell in the body. To the immune system, that seam looks foreign. So the vaccine in this trial is simply that seam. A peptide twenty-four amino acids long, made in a lab, injected under the skin alongside something that tells the immune system to pay attention.
Two things make this seam remarkable. The tumor cannot drop it, because it is the engine. And because the break always falls in the same place, the seam is identical from patient to patient. One vaccine fits everyone with this disease.
The vaccine raises T cells. A tumor can still switch them off, so it is given with two antibodies, nivolumab and ipilimumab, that release the brakes on T cells.
The first results came out in twenty twenty-five. Sixteen patients enrolled and twelve finished the vaccine course. Nine of the twelve developed T cells that recognized the seam, where only one had them at the start. Nine had their disease held in check, and three tumors shrank by at least a third. Every patient who responded also developed those T cells, which is the link the trial was built to test. A thirteen-year-old was still responding after two years. Side effects were mostly sore injection sites, headache and fatigue, though about a third of patients had a more serious reaction to the antibodies.
And when the cancer did escape, the tumor had not hidden the seam. The T cells had worn out, which is a different and more tractable problem.
The trial continues at Johns Hopkins, led by Mark Yarchoan, and now includes other cancers that carry the same fusion.
Everything in this film comes from the published record, and it is not medical advice.
Sources behind this film
Honeyman JN. Science, 2014
Most liver cancer follows decades of hepatitis, alcohol or fatty liver; fibrolamellar does not; A stretch of chromosome nineteen about four hundred thousand letters long went missing, fusing two neighboring genes; One gene makes a chaperone; the other the working half of protein kinase A; joined they still work as an enzyme; In all fifteen tumors examined, in none of the normal liver beside them (+1 more lines)
Most liver cancer follows decades of hepatitis, alcohol or fatty liver; fibrolamellar does not
Baretti M. Nat Med, 2025
Median age twenty-four in this trial; youngest patient twelve; No standard drug treatment; half of those patients live about a year; Blocking the enzyme failed; protein kinase A is essential everywhere; the target was called undruggable; The seam exists in no healthy cell; the vaccine is that seam, twenty-four amino acids, injected with something that gets the immune system's attention (+11 more lines)
Median age twenty-four in this trial; youngest patient twelve; Surgery can cure it if the whole tumor can be removed; Sixteen enrolled, twelve finished the course; Mostly sore injection sites, headache, fatigue; about a third had a more serious reaction to the antibodies (+1 more lines)
Zack T. NPJ Precis Oncol, 2023
About six hundred new US cases a year
Glavas D. J Gastrointest Surg, 2023
Surgery can cure it if the whole tumor can be removed
Surgery can cure it if the whole tumor can be removed
The drug
1. DNAJB1-PRKACA peptide vaccine: Day 1, 8, 15 of cycle 1 and on Day 1 of cycle 2, 3 and 4 (priming phase). Boost vaccinations: every 3 cycles beginning C5D1.
1. Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 1-4 during the priming phase. Boost/maintenance vaccinations will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 5.
The study
The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC and with non-FLC solid tumors and to assess the T-cell response.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.